Psoriatic Arthritis Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies – UCB Biopharma, AbbVie, Bristol-Myers Squibb, Sun Pharma

March 14 01:42 2023
Psoriatic Arthritis Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - UCB Biopharma, AbbVie, Bristol-Myers Squibb, Sun Pharma

DelveInsight’s “Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Psoriatic Arthritis, historical and forecasted epidemiology as well as the Psoriatic Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Psoriatic Arthritis Overview

Psoriatic arthritis is a heterogeneous chronic inflammatory rheumatic disease characterized by pain, stiffness, swollen joints, joint erosion, and bone formation. It can present with oligoarticular joint involvement that is typically asymmetric or as a polyarticular disease affecting five or more joints, usually with asymmetric distribution similar to that of rheumatoid arthritis.

Some of the key facts of the Psoriatic Arthritis Market Report:

  • Psoriatic arthritis market size is anticipated to increase with a significant CAGR during the study period 2019-32.
  • According to the National Psoriatic foundation, about 1 in 3 people or 30% with psoriasis develop psoriatic arthritis.
  • Psoriatic Arthritis epidemiology based on gender analyzed that Psoriatic Arthritis diagnosis is same in all genders.
  • Psoriatic Arthritis epidemiology based on severity analyzed that the prevalence of the severe cases is the highest.
  • According to the National Institute for Health and Clinical Excellence, the prevalence of psoriatic arthritis in the UK is estimated to be around 0.1% to 0.3% of the total population.
  • Psoriatic Arthritis key companies such as UCB Biopharma, AbbVie, Bristol-Myers Squibb, Sun Pharma and others are working towards developing the Psoriatic Arthritis drugs.
  • Psoriatic Arthritis emerging therapies like Ilumya (tildrakizumab-asmn), Deucravacitinib, NDI-034858, Bimekizumab, Brepocitinib are expected to change the dynamics of the Psoriatic Arthritis market.

Request a sample for the Psoriatic Arthritis Market Report

Key benefits of the Psoriatic Arthritis Market report:

  1. Psoriatic Arthritis market report covers a descriptive overview and comprehensive insight of the Psoriatic Arthritis Epidemiology and Psoriatic Arthritis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Psoriatic Arthritis market report provides insights on the current and emerging therapies.
  3. Psoriatic Arthritis market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Psoriatic Arthritis market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Psoriatic Arthritis market.

The Report Covers the Psoriatic Arthritis Epidemiology, Segmented by –

  • Total Incident Cases of Psoriatic Arthritis in the 7MM (2019–2032)
  • Gender-specific Cases of Psoriatic Arthritis in the 7MM (2019–2032)
  • Age-specific Cases of Psoriatic Arthritis in the 7MM (2019–2032)
  • Mutation-specific Cases of Psoriatic Arthritis in the 7MM (2019–2032)
  • Treated Cases of Psoriatic Arthritis by the line of therapies in the 7MM (2019–2032)
  • Treated Cases of Psoriatic Arthritis by status in the 7MM (2019–2032)

Psoriatic Arthritis Market 

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Psoriatic Arthritis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Psoriatic Arthritis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Psoriatic Arthritis Drugs Uptake and Pipeline Development Activities

The drugs’ uptake section focuses on the rate of uptake of the potential drugs recently launched in the Psoriatic Arthritis market or expected to be launched during the study period. The analysis covers the Psoriatic Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

The report’s drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Psoriatic Arthritis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Psoriatic Arthritis Unmet Needs

  • Challenges in Psoriatic Arthritis diagnosis
  • Development of novel therapies
  • Limitations in gene therapy
  • Poor Psoriatic Arthritis undertaking
  • Clinical biomarkers

Learn more by requesting for sample @ Psoriatic Arthritis Market Landscape 

Psoriatic Arthritis Pipeline Therapies and Key Companies 

  • Ilumya (tildrakizumab-asmn): Sun Pharma
  • Deucravacitinib: Bristol-Myers Squibb
  • NDI-034858: Nimbus Therapeutics
  • Bimekizumab: UCB Biopharma
  • Brepocitinib: Pfizer

Table of Contents

1. Psoriatic Arthritis Market Report Introduction

2. Executive Summary for Psoriatic Arthritis

3. SWOT analysis of Psoriatic Arthritis

4. Psoriatic Arthritis Patient Share (%) Overview at a Glance

5. Psoriatic Arthritis Market Overview at a Glance

6. Psoriatic Arthritis Disease Background and Overview

7. Psoriatic Arthritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Psoriatic Arthritis 

9. Psoriatic Arthritis Current Treatment and Medical Practices

10. Psoriatic Arthritis Unmet Needs

11. Psoriatic Arthritis Emerging Therapies

12. Psoriatic Arthritis Market Outlook

13. Country-Wise Psoriatic Arthritis Market Analysis (2019–2032)

14. Psoriatic Arthritis Market Access and Reimbursement of Therapies

15. Psoriatic Arthritis Market drivers

16. Psoriatic Arthritis Market barriers

17.  Psoriatic Arthritis Appendix

18. Psoriatic Arthritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Psoriatic Arthritis Pipeline 

“Psoriatic Arthritis Pipeline Insight, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Psoriatic Arthritis market. A detailed picture of the Psoriatic Arthritis pipeline landscape is provided, which includes the disease overview and Psoriatic Arthritis treatment guidelines.

Psoriatic Arthritis Epidemiology

DelveInsight’s ‘Psoriatic Arthritis Epidemiology Forecast to 2032’ report delivers an in-depth understanding of the disease, historical and forecasted Psoriatic Arthritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Navdha Goel
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States